Page 1 of 1
Parexcel is the CRO
Posted: Sat Feb 02, 2019 12:34 am
by biopearl123
Re: Parexcel is the CRO
Posted: Sat Feb 02, 2019 5:54 am
by huntingonthebluffs
Re: Parexcel is the CRO
Posted: Sat Feb 02, 2019 7:32 pm
by karagozoglu12345
Compensation levels seem to be high for a stock that has been trading near its cash value. I understand that getting talent on board is a costly endevour. But, I would think there has to be some way to tie compensation to results. I wonder what was the rationale for Dr. Scarlett's bonus ( 280,000$) in 2018 which was a disasterous year for the investors?
Re: Parexcel is the CRO
Posted: Sun Feb 03, 2019 1:26 am
by nerdyboy99
'C' level compensation has absolutely no tie to how shareholders fared. Bonuses are negotiated and offered as part of an overall compensation package.
I, for one, read the post-continuation documents and ASH follow ups and I am very happy with the way this shipped is being righted. I feel the compensation is adaquet in this very competative landscape. Scarlet is doing a good job. 2019 will be a big year.
"Disastrous"?
I have a substantial position and I haven't lost a cent. I am confident on the future of Geron. What disaster?
Re: Parexcel is the CRO
Posted: Sun Feb 03, 2019 4:55 am
by karagozoglu12345
What disaster? If your cost basis was near cash value then you wouldn't loose a cent on paper. There are many of us who had been mislead by Janssen before CD with cost basis over 5$. Yes, so far it has been a disaster for me. I hope tide will turn this year.
I agree that bonuses are most likely negotiated as part of the overall compensation package. Salaries are generally stable irrespective of a company's performance. Should bonus not be a function of performance as well? By definition bonus serves as a reward for good performance.